focused on CD68 expression in various types of cancer and reported that high CD68 levels in tumor samples correlated with adverse prognosis in glioblastoma, kidney renal clear cell carcinoma, lower-grade glioma, hepatocellular carcinoma, lung squamous cell carcinoma, thyroid carcinoma, and thymoma. This evidence concerns the gene CD68 and hepatocellular carcinoma.